BioRender key facts
as of Oct 2026- Developer of a science illustration software designed to empower the world to learn and communicate science through visuals.
- BioRender is valued at approximately $900.0M as of Oct 2026 (last reported valuation).
- It has raised $17.2M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Y Combinator, Sequoia Capital, Liquid 2 Ventures, FundersClub, Fifty Years — 21 tracked in total.
- Status: Privately Held (backing).
BioRender's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch BioRender: the Monday email on marks, rounds and moves
BioRender funding rounds
No funding rounds for BioRender are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs BioRender
21+BioRender valuation
BioRender's last reported valuation was $900 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
BioRender investors
21 investors are on record for BioRender, including Y Combinator, Sequoia Capital, Liquid 2 Ventures and FundersClub. By type, the record holds 8 venture capital firms and 1 angel investor.
About BioRender
Developer of a science illustration software designed to empower the world to learn and communicate science through visuals. The company's platform enables scientists to create their compositions without drawing, export their custom images in their preferred format, and showcase their research, allowing scientist to quickly and easily communicate their findings.
- Sector
- Information Technology
- HQ
- Toronto, Canada
- Founded
- 2017
- Employees
- 238
- Website
- biorender.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.